Additionally, 17 cases developing macrophage activation syndrome (MAS) were administered tocilizumab (IL-6 antagonist) and 16 cases meeting the criteria published in the national guidelines for COVID-19 treatment in adult patients received convalescent (immune) plasma [16]. Here, IL6 is linked to macrophage activation syndrome.